Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
VJOncology avatar; VJ Oncology @VJOncology ·
July 24, 2024 1816217008591020204

🎥@AlexisLevee of @CityofHope discusses a study on gut microbiome's link to response in metastatic #breastcancer treated with ICIs. Future studies aim to personalize treatments and develop probiotics:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #ImmunoOnc #BCsm

Image for twitter card

Using gut microbiota to enhance immunotherapy for breast cancer

Alexis Ann LeVee, MD, City of Hope, Duarte, CA, comments on a Phase I/II study (NCT02778685) that revealed the g...

ow.ly
Reply on Twitter 1816217008591020204 Retweet on Twitter 1816217008591020204 0 Like on Twitter 1816217008591020204 2 Twitter 1816217008591020204
VJOncology avatar; VJ Oncology @VJOncology ·
July 24, 2024 1816154875320791124

🎥@drlauragoff of @VUMC_Cancer discusses the CheckMate 9DW trial, showing nivolumab + ipilimumab improved OS in advanced HCC vs. sorafenib or lenvatinib, outperforming IMbrave150 and HIMALAYA trials:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #CTSM #ImmunoOnc #HPBCsm

Image for twitter card

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate ...

ow.ly
Reply on Twitter 1816154875320791124 Retweet on Twitter 1816154875320791124 4 Like on Twitter 1816154875320791124 10 Twitter 1816154875320791124
Load More

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
July 24, 2024 1816217008591020204

🎥@AlexisLevee of @CityofHope discusses a study on gut microbiome's link to response in metastatic #breastcancer treated with ICIs. Future studies aim to personalize treatments and develop probiotics:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #ImmunoOnc #BCsm

Image for twitter card

Using gut microbiota to enhance immunotherapy for breast cancer

Alexis Ann LeVee, MD, City of Hope, Duarte, CA, comments on a Phase I/II study (NCT02778685) that revealed the g...

ow.ly
Reply on Twitter 1816217008591020204 Retweet on Twitter 1816217008591020204 0 Like on Twitter 1816217008591020204 2 Twitter 1816217008591020204
VJOncology avatar; VJ Oncology @VJOncology ·
July 24, 2024 1816154875320791124

🎥@drlauragoff of @VUMC_Cancer discusses the CheckMate 9DW trial, showing nivolumab + ipilimumab improved OS in advanced HCC vs. sorafenib or lenvatinib, outperforming IMbrave150 and HIMALAYA trials:

➡️⬅️

@ASCO @OncoAlert #ASCO24 #CTSM #ImmunoOnc #HPBCsm

Image for twitter card

CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate ...

ow.ly
Reply on Twitter 1816154875320791124 Retweet on Twitter 1816154875320791124 4 Like on Twitter 1816154875320791124 10 Twitter 1816154875320791124
Load More

Watch all videos from ASCO GU 2023!

View all videos
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023

Bladder Cancer at ASCO GU 2023!

View all
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
4:38
Impact of neoadjuvant chemo on pathological staging and survival in sarcomatoid bladder cancer
Arya Mariam Roy • 18 Feb 2023
1:45
Results from dataset analysis of CDH1-mutated urothelial carcinoma patients
Andrea Necchi • 18 Feb 2023
1:18
Updates from KEYNOTE-905: immunotherapy + cystectomy vs cystectomy alone in MIBC
Andrea Necchi • 18 Feb 2023

Prostate Cancer at ASCO GU 2023!

View all
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023
1:01
Updates from ECHOS: real world outcomes from mCSPC treatment with docetaxel
Orazio Caffo • 17 Feb 2023
0:55
Post-progression therapies in patients with mCRPC progressing after docetaxel
Orazio Caffo • 17 Feb 2023
1:10
Challenges facing new pathway inhibitor treatments in prostate cancer
Kamal Sahu • 16 Feb 2023

Kidney Cancer at ASCO GU 2023!

View all
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
The content of VJOncology is intended for healthcare professionals